Literature DB >> 23833155

Shared decision making in prostate-specific antigen testing with men older than 70 years.

Jun Li1, Zahava Berkowitz, Thomas B Richards, Lisa C Richardson.   

Abstract

BACKGROUND: Little is known about how shared decision making (SDM) is being carried out between older men and their health care providers. Our study aimed to describe the use of SDM key elements and assess their associations with prostate-specific antigen (PSA) testing among older men.
METHODS: We conducted descriptive and logistic regression modeling analyses using the 2005 and 2010 National Health Interview Survey data.
RESULTS: Age-specific prevalence of PSA testing was similar in 2005 and 2010. In 2010, 44.1% of men aged ≥70 years had PSA testing. Only 27.2% (95% confidence interval, 22.2-32.9) of them reported having discussions about both advantages and disadvantages of testing. Multiple regression analyses showed that PSA-based screening was positively associated with discussions of advantages only (P < .001) and with discussions of both advantages and disadvantages (P < .001) compared with no discussion. Discussion of scientific uncertainties was not associated with PSA testing.
CONCLUSIONS: Efforts are needed to increase physicians' awareness of and adherence to PSA-based screening recommendations. Given that discussions of both advantages and disadvantages increased the uptake of PSA testing and discussion of scientific uncertainties has no effect, additional research about the nature, context, and extent of SDM and about patients' knowledge, values, and preferences regarding PSA-based screening is warranted.

Entities:  

Keywords:  Aged; Prostate Cancer; Prostate-specific Antigen; Screening; Shared Decision Making

Mesh:

Substances:

Year:  2013        PMID: 23833155      PMCID: PMC4480614          DOI: 10.3122/jabfm.2013.04.120267

Source DB:  PubMed          Journal:  J Am Board Fam Med        ISSN: 1557-2625            Impact factor:   2.657


  26 in total

1.  Predictive margins with survey data.

Authors:  B I Graubard; E L Korn
Journal:  Biometrics       Date:  1999-06       Impact factor: 2.571

2.  Knowledge, attitudes, and screening practices among older men regarding prostate cancer.

Authors:  C B Steele; D S Miller; C Maylahn; R J Uhler; C T Baker
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

3.  Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy.

Authors:  Karen E Hoffman; Paul L Nguyen; Andrea K Ng; Anthony V D'Amico
Journal:  J Urol       Date:  2010-03-17       Impact factor: 7.450

4.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391

5.  Prostate-specific antigen screening for prostate cancer in older men in the United States of America.

Authors:  Amanda Black; Christine D Berg
Journal:  Gerontology       Date:  2012-02-16       Impact factor: 5.140

6.  Discussions about prostate cancer screening between U.S. primary care physicians and their patients.

Authors:  Ingrid J Hall; Yhenneko J Taylor; Louie E Ross; Lisa C Richardson; Thomas B Richards; Sun Hee Rim
Journal:  J Gen Intern Med       Date:  2011-03-18       Impact factor: 5.128

7.  Prevalence of cancer screening in older, racially diverse adults: still screening after all these years.

Authors:  Keith M Bellizzi; Erica S Breslau; Allison Burness; William Waldron
Journal:  Arch Intern Med       Date:  2011-12-12

8.  Prostate cancer screening trends of New York State men at least 50 years of age, 1994 to 1997.

Authors:  K McDavid; T A Melnik; H Derderian
Journal:  Prev Med       Date:  2000-09       Impact factor: 4.018

9.  Use of the prostate-specific antigen test among men aged 75 years or older in the United States: 2006 Behavioral Risk Factor Surveillance System.

Authors:  Jun Li; Guixiang Zhao; Lori A Pollack; Judith Lee Smith; Djenaba A Joseph
Journal:  Prev Chronic Dis       Date:  2010-06-15       Impact factor: 2.830

10.  Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database.

Authors:  Robert A Stephenson
Journal:  Urol Clin North Am       Date:  2002-02       Impact factor: 2.241

View more
  6 in total

1.  Decrease in Prostate Cancer Testing Following the US Preventive Services Task Force (USPSTF) Recommendations.

Authors:  Jun Li; Zahava Berkowitz; Ingrid J Hall
Journal:  J Am Board Fam Med       Date:  2015 Jul-Aug       Impact factor: 2.657

2.  Pre-screening Discussions and Prostate-Specific Antigen Testing for Prostate Cancer Screening.

Authors:  Jun Li; Guixiang Zhao; Ingrid J Hall
Journal:  Am J Prev Med       Date:  2015-05-18       Impact factor: 5.043

3.  Prostate cancer screening decision-making in three states: 2013 behavioral risk factor surveillance system analysis.

Authors:  Jun Li; Ingrid J Hall; Guixiang Zhao
Journal:  Cancer Causes Control       Date:  2017-02-16       Impact factor: 2.506

4.  Prostate-Specific Antigen Testing Initiation and Shared Decision-Making: Findings from the 2000 and 2015 National Health Interview Surveys.

Authors:  Jun Li; Helen Ding; Thomas B Richards; Iman Martin; Sarah Kobrin; Pamela M Marcus
Journal:  J Am Board Fam Med       Date:  2018 Jul-Aug       Impact factor: 2.657

Review 5.  Opportunities and challenges for the use of large-scale surveys in public health research: a comparison of the assessment of cancer screening behaviors.

Authors:  Jada G Hamilton; Nancy Breen; Carrie N Klabunde; Richard P Moser; Bryan Leyva; Erica S Breslau; Sarah C Kobrin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-09       Impact factor: 4.254

6.  Public knowledge of chronic kidney disease evaluated using a validated questionnaire: a cross-sectional study.

Authors:  Pankti A Gheewala; Gregory M Peterson; Syed Tabish R Zaidi; Matthew D Jose; Ronald L Castelino
Journal:  BMC Public Health       Date:  2018-03-20       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.